According to our recent payer coverage analysis for immune globulin treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A market access breakdown by reimbursement channel shows some differences in immune globulin product coverage. Commercial and health exchange formulary coverage is roughly equivalent, whereas medicare formularies have a slightly greater percentage of covered lives.
Source: MMIT data as of Q4 2016
Trends: Recent news related to immune globulin products shows some trends in prescriber habits and overall market drivers. Due to the cost of IVIG treatments and the supply of treatments, the new medicare drug demo is creating some concerns across the industry. While certain patient populations and physician advocate the program, most pharmaceutical manufacturers and some physicians serving senior populations are at odds with the value of the initiative. Developments in the administration of immune globulin treatments, highlighted by late-phase pipeline and new-to-market products opens up potential market share for more innovative products.
In the full Reality Check on immune globulin treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.
To read the full Reality Check on immune globulin treatments with key findings on clinical characteristics, IVIG drug market access and payer coverage, please click on the button below: